KRMAYURVED KRM Ayurveda Q4 FY26 results (Jan–Mar 2026) and concall
KRM Ayurveda Limited delivered a strong financial performance in FY26, with significant growth in revenue, EBITDA, and PAT, alongside substantial margin expansion. The company is now debt-free and is embarking on an aggressive expansion strategy, planning to significantly increase its bed capacity and clinic network across India, supported by a system-driven model and strategic capital allocation. Management expressed confidence in sustained growth and profitability, driven by both services and an expanding product portfolio.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|
| Revenue | 41 | 25 | 48 | 32 |
| EBITDA | 8 | 6 | 13 | 11 |
| Net profit | 5 | 4 | 8 | 8 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
